Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

Lorlatinib is currently the most advanced, potent and selective anaplastic lymphoma kinase
(ALK) tyrosine kinase inhibitor for the treatment of ALK-positive non-small cell lung cancer in …

Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …